The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial [PDF]
Arthritis Research and TherapyBackground Patients with rheumatoid arthritis (RA) have an increased prevalence of comorbidities, which is associated with higher RA disease activity and worse disease outcomes.
Eugen Feist +2 more
exaly +5 more sources
Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19 [PDF]
Reviews in Cardiovascular Medicine, 2021 No abstract present.
VÍCTOR L Serebruany
exaly +5 more sources
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment [PDF]
Современная ревматологияObjective. To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with active rheumatoid arthritis (RA), using pooled data from three randomised clinical trials (RCT) followed by open-label ...
Eugen Feist +9 more
doaj +4 more sources
Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis [PDF]
Journal of Personalized Medicine, 2022 Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease and its treatment is an urgent problem of rheumatology. Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 and is one of the few promising drugs for RA therapy. One-hundred-and-twenty-five DNA samples from Russian patients with RA, treated with olokizumab, were ...
D S Mikhaylenko +2 more
exaly +4 more sources
The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis [PDF]
Clinical Rheumatology, 2023 Abstract Olokizumab (OKZ) is a novel IL-6 inhibitor that directly targets IL-6 rather than its receptor. We aim to evaluate the efficacy and safety of OKZ for patients with rheumatoid arthritis (RA) and to investigate the optimal treatment regimen. A systematic review, pairwise, and network meta-analysis synthesizing randomized controlled trials (RCTs)
Mohamed Abuelazm +2 more
exaly +4 more sources
Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period [PDF]
PharmaceuticalsBackground/Objectives: This study aimed to evaluate the pharmacokinetics (PK), effectiveness, and safety of the direct interleukin-6 (IL-6) inhibitor olokizumab (OKZ) in adolescent patients with active polyarticular juvenile idiopathic arthritis (pJIA ...
Ekaterina I. Alexeeva +11 more
doaj +2 more sources
Direct interleukin-6 inhibitor olokizumab in the treatment of polymyalgia rheumatica: a case series [PDF]
Frontiers in MedicineObjectiveTo describe the experience of using olokizumab (OKZ) in patients with polymyalgia rheumatica (PMR) who have contraindications or an inadequate response to methotrexate and require steroid-sparing therapy, and to analyze treatment outcomes in ...
Alexey D. Meshkov +11 more
doaj +2 more sources
A Novel Humanized Anti-Interleukin-6 Antibody HZ0408b With Anti-Rheumatoid Arthritis Therapeutic Potential [PDF]
Frontiers in Immunology, 2022 Interleukin-6 (IL-6), a pleiotropic cytokine that regulates immune responses and inflammatory reactions, plays a pivotal role in the development of rheumatoid arthritis (RA).
Xiaolei Liu +9 more
doaj +2 more sources
Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis [PDF]
Journal of Translational MedicineBackground Difficult-to-treat Rheumatoid arthritis (D2T RA) is primarily characterised by failure of at least two different mechanism of action biologic/targeted synthetic disease-modifying antirheumatic drug (DMARDs) with evidence of active/progressive ...
Qin-Yi Su +8 more
doaj +2 more sources
Научно-практическая ревматология, 2021 Background. Olokizumab is a new interleukin-6 (IL-6) inhibitor that has demonstrated good efficacy and safety for the treatment of adult patients with moderate to high-grade activity of rheumatoid arthritis in combination with methotrexate with ...
E. L. Nasonov +3 more
doaj +1 more source